France

On 2 October 2026, the French National Authority for Health (HAS) issued a favorable opinion on the conditional coverage of shape-sensing robotic-assisted bronchoscopy (ssRAB) using the Ion system under the Forfait Innovation program. As robotic surgery in general does not have formal recognition within the reimbursement system in France, this represents a significant step towards potential recognition. Also, this is the first potential Forfait Innovation project focused on robotic surgery, indicating the program's potential boundaries for innovative invasive technologies in France.

On October 5, 2026, the updated version of the intra-DRG list was published in France. Two new devices were registered in the neurovascular field (thromboaspiration catheters CEREGLIDE 92 and Broadway 8). Other changes included a few delistings and renewal and/or modification of registration conditions for several devices.

In September 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued supporting add-on reimbursement for two devices in the cardiovascular and breast reconstruction fields, as well as the registration of several medical aids, including an automated insulin delivery system.

On September 10, 2026, the Ministry of Health in France announced nine projects selected for the 2025-2026 Health Economic Research Program (PRME), including four MedTech-related projects concerning nuclear imaging, in vitro diagnostics, treatment of thrombocytopenia, and endoscopic procedures in gastroenterology.

On September 11, 2026, the French National Authority for Health (HAS) published its favorable opinion on the coverage of the SAPIEN M3 transcatheter mitral valve replacement system under the Forfait innovation program.

In August 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). One favorable opinion was issued supporting add-on reimbursement for a new cardiovascular device.

In July 2026, the French National Authority for Health (HAS) updated its guidance on submitting dossiers for an economic opinion by the Economic and Public Health Evaluation Commission (CEESP). The update includes a procedural guide on pre-submission meetings with the HAS Economic Evaluation Service. These meetings are intended to help manufacturers identify the most appropriate methodological choices and prepare economic evaluations that are consistent with HAS recommendations.

On August 6, 2026, the French Ministry of Health published the instruction for the 2026/27 application campaign for coverage with evidence development programs. The instruction outlines the research priorities, eligibility criteria, application procedures, and timelines for the different programs, including PHRC, PRME, PREPS, PHRIP, and PRT.

In July 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favorable opinions were issued supporting add-on reimbursement for one new device and an extension of the reimbursed indications for another, in the gastrointestinal and peripheral vascular fields.

In July 2026, the French Ministry of Health granted early coverage under the PECAN scheme to a digital medical device (Poppins Clinical) for the rehabilitation of specific learning disorders involving reading deficits. Since the scheme's inception in 2023, all devices granted early coverage have been intended for remote patient monitoring. The decision on Poppins Clinical marks the first PECAN coverage of a therapeutic digital medical device.

In July 2026, the French National Authority for Health established MiMED department within its Directorate for Evaluation and Access to Innovation. The new department will modernize health technology assessment methods, strengthen the use of real-world data, and support France's contribution to European HTA coordination.

In June 2026, the French National Authority for Health (HAS) published new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following its meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Favourable opinions were issued on the add-on reimbursement for 14 new devices and on the extension of indications for one device, in different medical fields.